US 12,383,617 B2
Compositions and methods concerning immune tolerance
Jeffrey A. Hubbell, Chicago, IL (US); David Scott Wilson, Chicago, IL (US); Kym Brünggel, Chicago, IL (US); and Kristen Marie Lorentz, Ecublens (CH)
Assigned to The University of Chicago, Chicago, IL (US); and Anokion SA, Ecublens (CH)
Appl. No. 17/250,015
Filed by The University of Chicago, Chicago, IL (US); and Anokion SA, Ecublens (CH)
PCT Filed May 9, 2019, PCT No. PCT/US2019/031440
§ 371(c)(1), (2) Date Nov. 3, 2020,
PCT Pub. No. WO2019/217628, PCT Pub. Date Nov. 14, 2019.
Claims priority of provisional application 62/669,044, filed on May 9, 2018.
Prior Publication US 2021/0244812 A1, Aug. 12, 2021
Int. Cl. A61K 39/385 (2006.01); A61K 39/00 (2006.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61P 37/06 (2006.01); C07D 249/16 (2006.01); C08F 220/58 (2006.01); C08G 65/332 (2006.01); C08G 65/334 (2006.01); C08G 81/02 (2006.01)
CPC A61K 39/385 (2013.01) [A61K 39/0008 (2013.01); A61K 39/001154 (2018.08); A61K 39/001158 (2018.08); A61K 39/4611 (2023.05); A61K 39/4644 (2023.05); A61K 47/549 (2017.08); A61K 47/60 (2017.08); A61P 37/06 (2018.01); C07D 249/16 (2013.01); C08F 220/58 (2013.01); C08G 65/332 (2013.01); C08G 65/3344 (2013.01); C08G 81/025 (2013.01); A61K 2039/6087 (2013.01); A61K 2039/6093 (2013.01); A61K 2239/38 (2023.05)] 17 Claims
 
1. A compound of Formula 1:
X—[Y(Z)p]m—R2   Formula 1
where:
X comprises an antigen, a tolerogenic portion thereof, or a mimetic thereof;
Y comprises a linker moiety;
Z comprises a moiety that specifically targets a mannose receptor;
p is an integer from 2 to 250;
m is an integer from 1 to 100;
R2 is any of functional groups I-III:

OG Complex Work Unit Chemistry
where Ar is a substituted or unsubstituted aromatic group and one or more of:
R3 is C1-6-alkyl; or
R11 is C1-6-alkyl.
 
15. A composition comprising the compound of claim 1.